KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) Research & Development (2016 - 2025)

Eli Lilly's Research & Development history spans 17 years, with the latest figure at $3.8 billion for Q4 2025.

  • For Q4 2025, Research & Development rose 25.76% year-over-year to $3.8 billion; the TTM value through Dec 2025 reached $13.3 billion, up 21.34%, while the annual FY2025 figure was $13.3 billion, 21.34% up from the prior year.
  • Research & Development reached $3.8 billion in Q4 2025 per LLY's latest filing, up from $3.5 billion in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $3.8 billion in Q4 2025 to a low of $1.6 billion in Q1 2022.
  • Average Research & Development over 5 years is $2.4 billion, with a median of $2.4 billion recorded in 2023.
  • Peak YoY movement for Research & Development: decreased 3.71% in 2022, then surged 33.62% in 2023.
  • A 5-year view of Research & Development shows it stood at $1.9 billion in 2021, then rose by 5.14% to $2.0 billion in 2022, then increased by 28.38% to $2.6 billion in 2023, then rose by 17.98% to $3.0 billion in 2024, then grew by 25.76% to $3.8 billion in 2025.
  • Per Business Quant, the three most recent readings for LLY's Research & Development are $3.8 billion (Q4 2025), $3.5 billion (Q3 2025), and $3.3 billion (Q2 2025).